NGF and Alzheimer’s disease: a model for trophic factor therapy in neurodegeneration
A review on recent research progress in neurotrophic factors and their implication for experimental therapy of Alzheimer’s disease is given. The status of NGF mechanisms in AD is not fully understood, although NGF administration in animal studies is suggested to counter at cholinergic atrophy present in AD. Limited clinical trials have been performed with NGF in AD, and effective therapy in AD will require protection of vulnerable neuronal populations. The possibilities of NGF treatment of CNS diseases including AD are intracerebral infusion, slow-releasing implants, implantation of cells producing recombinant NGF or local injection of genetic material producing active fragments or small molecules that pass the blood-brain barrier. NGF administration is expected to improve functional performance of surviving cells, but larger clinical trials are needed to confirm preliminary encouraging results of neurotrophic factor therapy.
KeywordsNerve Growth Factor Neurotrophic Factor Cholinergic Neuron Basal Forebrain Basal Forebrain Cholinergic Neuron
Unable to display preview. Download preview PDF.
- DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RAE, Chui HC, Knopman DS, Reeder TM, Shetter AG, Senter HJ, Markesbery WR and the Intraventricular Bethanechol Study Group (1992) Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Ann Neurol 32:625–632.PubMedCrossRefGoogle Scholar
- Francis PT, Palmer AM, Sioms NR, Bowen DM, Davison AN, Esiri MM, Neary D (1985) Neurochemical studies of early-onset Alzheimer’s disease. Possible influence on treatment. Lancet 4:7–11.Google Scholar
- Hefti F (1993) Neurotrophic factor therapy for nervous system degenerative diseases. Neuron (in press).Google Scholar
- Hefti F, Schneider LS (1989) Rationale for the planned clinical trials with nerve growth factor in Alzheimer’s disease. Psych Dev 4:297–315.Google Scholar
- Kaplan DR, Perkins A, Morrison DK (1992) Signal transduction by receptor tyrosine kinases. In: McGuire WL (ed) Oncogenes and tumor suppressor genes in human malignancies. Kluwer Academic Publishers, Norwell MA.Google Scholar
- Knüsel B, Beck Kd, Winslow JW, Rosenthal A, Burton LE, Widmer HR, Nikolics K, Hefti F (1992a) Brain derived neurotrophic factor administration protects basal forebrain cholinergica but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci 12: 4391–4402.PubMedGoogle Scholar
- Lehericy S, Hirsch EC, Cervera-Pierot P, Hersh LB, Bakchine S, Piette F, Duyckaerts Cerebrolysin Hauw JJ, Javoy-Agid F, Agid Y (1993) Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease J Comp Neurol 330:15–31.PubMedCrossRefGoogle Scholar
- Olson L, Nordberg A, von Holst H, Backman L, Ebendahl T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, Lundquist H, Langstron B, Meyerson B, Persson A, Viitanen M, Winblad B, Seiger A (1992) Nerve growth factor affects 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient. J Neural Transm [P-D Sect] 4:79–95.CrossRefGoogle Scholar
- Pardridge WM (1991) Transnasal and intraventricular delivery of drugs. In: Pardridge WM (ed) Peptide drug delivery to the brain. Raven Press, New York, pp 99–122.Google Scholar
- Sofroniew MV, Isacson O (1988) Distribution of degeneration of cholinergic neurons in the septum following axotomy in different portions of the fimbria-fornix: a correlation between cell loss and proximity to the lesion. J Chem Neuroant 1:327–337.Google Scholar
- Touchette N (1993) Rising spirits for motor neuron revival. J NIH Res 5:53–59.Google Scholar